Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients

Phase I Trial of AVD Plus Lenalidomide (Revlimid) in Elderly Intermediate or Advanced Stage Hodgkin Lymphoma Patients

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01056679

Acronym

AVD-Rev

Enrollment

Registered

2010-01-26

Start date

2010-04-30

Completion date

2016-02-29

Last updated

2018-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hodgkin Lymphoma

Brief summary

The purpose of this study is to determine within the scope of the trial what the maximum tolerated dose (MTD) of lenalidomide in combination with AVD should be.

Interventions

DRUGDoxorubicine

50mg/m2 day 1 + 15

DRUGDTIC

375mg/m2 day 1 + 15

DRUGLenalidomide

day 1 - 21

DRUGVinblastine

6mg/m2 day 1 + 15

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

60 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Hodgkin Lymphoma, intermediate or advanced stage * Age \>60 and \<75 years * ECOG 2 or better * No major organ dysfunction * Ability to take aspirin or LMW Heparin

Exclusion criteria

* HL as composite lymphoma * Prior use of lenalidomide * Prior use of chemo- or radiotherapy

Design outcomes

Primary

Measure	Time frame
Dose limiting toxicities (DLT)	—

Secondary

Measure	Time frame
Overall response rate (ORR)	—
Progression free survival (PFS)	2 years

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026